Clinical Practice Session
Cardiovascular-Kidney-Metabolic Syndrome Case Discussions: From Trials to Patient Management, Including the Garabed Eknoyan, MD, Endowed Lectureship
November 08, 2025 | 10:30 AM - 12:30 PM
Location: General Assembly C, Convention Center
Session Description
Evidence-based practice for the management of diabetic kidney disease (DKD) has changed dramatically over the last five years and now includes four pillars of care, including RAAS inhibitors, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor agonists, and GLP-1 receptor agonists. Accordingly, clinical practice guidelines for the treatment of CKD have rapidly evolved to reflect this changing landscape. This session focuses on updated guidelines and uses case-based scenarios to discuss strategies for implementing guideline-directed therapies in patients with kidney diseases.
ASN gratefully acknowledges Wadi N. Suki, MD, for support of the Eknoyan Endowed Lectureship.
Learning Objective(s)
- Summarize the rationale and content of the KDIGO Clinical Practice Guidelines for management of CKD
- Explain the rationale for the sequential initiation of guideline-directed kidney-protective therapies
- Explain the rationale for the simultaneous initiation of guideline-directed kidney protective therapies
- Evaluate case-based discussions of clinical evidence and how to manage patients with DKD
Learning Pathway(s)
- Diabetic Kidney Disease
- Hypertension and Cardiorenal Disorders
Moderators
Presentations
- KDIGO Guidelines Decoded: What They Mean for CKD Management in Practice: The Garabed Eknoyan, MD, Endowed Lectureship
10:30 AM - 11:00 AM
- Step-by-Step: The Case for Sequential Treatment in CKD Management
11:00 AM - 11:30 AM
- All In at Once: Evidence for Simultaneous Treatment Initiation in CKD
11:30 AM - 12:00 PM
- From Evidence to Action: Case-Based Discussions on CKD Management
12:00 PM - 12:30 PM